Chronic kidney disease with hyperkalemia
Conditions
Interventions
Sodium polystyrene sulfonate
Calcium polystyrene sulfonate
Sponsors
Shonan Kamakura General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meets all the following standards 1)Patients with hyperkalemia(serum potassium is 5.5mEq/L or more) or receiving ion exchange resin for hyperkalemia 2)Outpatient 3)Patients with chronic kidney disease(stage G3-G5) 4)Patients over 20 years old at the time of giving consent 5)Patients giving written consent after being provided with sufficient explanation about participation in this clinical trial
Exclusion criteria
Exclusion criteria: Patients who corresponds to either of the following cannot participate in this clinical study 1)Patients on dialysis 2)Patients receiving oral hypoglycemic agents that might influence the insulin resistance (thiazolidine, biguanide, DPP-4 inhibitors, and drug combination comprising these component), insulin preparation, or GLP-1 receptor agonists 3)Patients who are allergic to targeted medication 4)Patients with intestinal obstruction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum potassium level | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Serum bicarbonate level 2)Arteriosclerosis-related examination (coronary calcification score, and pulse wave velocity) 3)Insulin resistant (HOMA-R) | — |
Countries
Japan
Contacts
Public ContactMachiko Oka
Shonan Kamakura General Hospital Dept. of Nephrology, Immunology and Vascular Medicine
Outcome results
None listed